国际标准期刊号: 2155-952X

生物技术与生物材料

开放获取

我们集团组织了 3000 多个全球系列会议 每年在美国、欧洲和美国举办的活动亚洲得到 1000 多个科学协会的支持 并出版了 700+ 开放获取期刊包含超过50000名知名人士、知名科学家担任编委会成员。

开放获取期刊获得更多读者和引用
700 种期刊 15,000,000 名读者 每份期刊 获得 25,000 多名读者

索引于
  • 哥白尼索引
  • 谷歌学术
  • 夏尔巴·罗密欧
  • 打开 J 门
  • Genamics 期刊搜索
  • 学术钥匙
  • 研究圣经
  • 中国知网(CNKI)
  • 访问全球在线农业研究 (AGORA)
  • 电子期刊图书馆
  • 参考搜索
  • 哈姆达大学
  • 亚利桑那州EBSCO
  • OCLC-世界猫
  • SWB 在线目录
  • 虚拟生物学图书馆 (vifabio)
  • 普布隆斯
  • 日内瓦医学教育与研究基金会
  • 欧洲酒吧
  • ICMJE
分享此页面

抽象的

Hyperdry Human Amniotic Membrane (HD-AM) is Supporting Aciclovir Included Device of Poly-N-p-Vinyl-Benzyl-D-Lactonamide (PVLA) Sphere for Treatment of HSV-1 Infected Rabbit Keratitis Model

Motonori Okabe, Toshiko Yoshida, Michiko Suzuki, Mitsuaki Goto, Masahiro Omori, Masato Taguchi, Ayaka Toda, Takuma Suzuki, Kazuaki Nakagawa, Fumitaka Hiramoto, Toyohiko Ushijima, Hiroki Waki, Etsuko Furuichi, Kenichi Arai, Kaixuan Zhou, Moustafa Fathy Omar, Makoto Nakamura, Yoshihiro Nomura, Toshio Kasama, Kiyoshi Katou, Shigeru Saito and Toshio Nika

The human amniotic membrane (AM) has been widely used in ophthalmic surgery, including in ocular surface reconstruction. However, whether AM is effective for the release of impregnated drugs is unknown. Hyperdry-AM (HD-AM), glutaraldehyde cross-linked HD-AM (Glu HD-AM) and a solvent of poly-N-p-vinylbenzyl- D-lactonamide (PVLA) did not cause irritation to the rabbit eye. Although the concentration of residual glutaraldehyde in Glu HD-AM was approximately 40 ppm (dry-weight basis), no eye irritation was observed. Acyclovir (ACV) containing PVLA-bearing spheres (ACV/PVLA) was loaded into HD-AM (ACV/PVLA HD-AM), and then the therapeutic efficacy of ACV/PVLA HD-AM was compared with that of ACV/PVLA solution in a herpes simplex virus-1 (HSV-1) eye infection model. The former was more effective against ocular infection, and its efficacy was dose- and volume-dependent. Thus, ACV/PVLA HD-AM sheets were very effective as a curative treatment for eye infection with HSV-1. HD-AM can be function as drug delivery system. In the future, it may be possible to combine HD-AM and PVLA in a device that can control the release of hydrophobic medicines.